New Blood-Cleansing device could help those who Can't take iron pills

NCT ID NCT06781099

Recruiting now Disease control Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This small study tests a device called MEX-CD1 that removes excess iron from the blood during a special type of dialysis. It is for people with myelodysplastic syndrome or myelofibrosis who have iron overload from blood transfusions but cannot take standard chelation therapy. Each participant will receive three short dialysis sessions over one week and be followed for 90 days to see if the device is safe and works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MEX-CD1 device for extracorporeal iron chelation
What this could lead to: If it works, this could offer a new way to manage iron overload in people who cannot tolerate standard chelation pills or injections.
What could go wrong: This is a very small early feasibility study (13 people) with no control group. The device is experimental, and it is unknown if it will be safe or effective enough for routine use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myelodysplastic syndrome Myelodysplastic Syndromes myelofibrosis primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELODYSPLASTIC SYNDROME MYELOFIBROSIS

Contacts and locations

Locations

Hôpital Lyon Sud
RECRUITING

Oullins-Pierre-Bénite, 69495, France
Hôpital Lyon Sud
RECRUITING

Oullins-Pierre-Bénite, 69495, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.